Amid a challenging year where mega-cap tech dominated, investment firm Giverny Capital outlines its contrarian stance, highlighting specialty insurer Kinsale Capital Group as a core holding despite recent underperformance.
Schweiter Technologies (SWTQ) has seen significant price swings on the SIX Swiss Exchange. With its current valuation trading well above industry peers, we examine whether the stock's optimistic growth prospects justify the premium or if investors should wait for a better entry point.
Sanofi reports a pivotal Phase 3 win for its investigational therapy venglustat in a rare neurological disorder, alongside positive EU regulatory news for Rezurock and progress for amlitelimab, signaling a strategic shift toward high-value specialty medicines.
REV Group shares have skyrocketed nearly 7x over five years, leaving investors to grapple with a critical question: has the rally run its course, or does the specialty vehicle manufacturer still offer value at current levels? We examine the valuation debate through multiple lenses.
As Michael Fiddelke steps into the CEO role, Target confronts a prolonged sales decline, intense competition, and escalating political tensions in its Minneapolis home base.
While low share prices often signal volatility, they can also hide significant upside. We analyze three companies trading under $10—Archer Aviation, Snap, and Opendoor Technologies—that are positioned to defy market expectations in the coming year, driven by sector tailwinds and strategic pivots.
Revvity (NYSE: RVTY) surged past fourth-quarter expectations and issued an upbeat 2026 outlook, driven by robust demand in its diagnostics division. The medical equipment maker's performance highlights a sector-wide resilience despite ongoing softness in academic research funding.
Palantir Technologies faces a critical earnings report as its shares, down 29% from their November peak, grapple with intense scrutiny over its sky-high valuation and shifting investor sentiment in the AI sector. The software firm must deliver strong guidance to prove its premium is warranted.
Prime Minister Jonas Gahr Stoere has publicly agreed with Crown Princess Mette-Marit's own assessment that she showed "poor judgement" in maintaining contact with convicted sex offender Jeffrey Epstein. The comments come as newly released court documents reveal extensive email correspondence, adding pressure on the Norwegian monarchy during a period of significant personal and institutional challenges.
The European Union's impending ban on Russian liquefied natural gas imports is poised to trigger orders for at least 30 new LNG tankers, as the bloc scrambles to reconfigure its energy supply chains ahead of key 2026-2027 deadlines.
The Rafah border crossing, Gaza's sole gateway to Egypt, has partially reopened for pedestrian traffic after a prolonged Israeli closure, offering a fragile hope for medical evacuations and family reunifications.
The U.S. Food and Drug Administration has issued a complete response letter for Aquestive Therapeutics' oral film drug designed to treat severe allergic reactions, the company announced Monday, delaying a potential new option for millions at risk.
The global payments giant reported a 15% surge in net revenue and processed a record 69.4 billion transactions in its fiscal first quarter, signaling resilient consumer confidence and a rebound from previous quarters.
A Dominus and Cheyne Capital partnership wins City of London approval to convert the Grade II-listed Ibex House into a 382-room hotel, slated for a late 2028 opening, complete with a hospitality academy and restored pub.
Amgen has transferred full rights for the atopic dermatitis drug rocatinlimab back to Kyowa Kirin, clearing the path for the Japanese firm to pursue US approval by 2026. The move comes despite the drug meeting all trial endpoints, reflecting Amgen's portfolio reprioritization and a tempered market outlook for the OX40 inhibitor class.
Cleveland-based KeyCorp (KEY) is riding a wave of positive analyst sentiment following a strong earnings beat, with its stock performance significantly outpacing broader market indices. The bank's diversified model and robust capital returns are fueling optimism for sustained growth.
Pharmaceutical giant Eli Lilly enters a strategic collaboration potentially worth up to $1.93 billion with biotech firm Repertoire Immune Medicines, aiming to develop precision treatments for autoimmune diseases that move beyond broad immunosuppression.
As mortgage rates fluctuate and ambitious policy ideas emerge, economists warn that financing tweaks cannot solve the core issue: a chronic shortage of homes.
Chinese biotech firm Arctic Vision moves to create an integrated ophthalmology powerhouse by acquiring MDCO Technology's device business, combining drug and device expertise to address unmet needs in eye care.
Despite a partial recovery, Pfizer's stock remains significantly below its pandemic-era peak. As 2026 approaches, the pharmaceutical giant confronts a critical juncture defined by looming patent expirations, a high-stakes catch-up effort in the lucrative GLP-1 market, and a dividend under pressure.
